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was non-significant for one health state. Kolmogorov Smirnov tests supported the 
results (two significant at 1%, one at 5% and one at 10%, the remaining being non-
significant. ConClusions: The first question in TTO questionnaires may induce 
anchoring in the final valuations.
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PeRfoRMance ScoRe extRaction fRoM Panel Data foR Multi-cRiteRia 
DeciSion analySiS (McDa) uSing a RegReSSion-BaSeD aPPRoach
Verbeek NA1, Tsiachristas A2, Franken M1, Koopmanschap MA1, Rutten-van Mölken MP1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University of Oxford, Oxford, UK
objeCtives: Key to effectively implementing MCDA is to ensure the performance 
matrix offers a valid comparison across alternatives. We propose to bring econo-
metric methods into the field of MCDA by estimating performance scores from 
patient-level panel data while matching on observable patient characteristics 
between different treatment alternatives. The aim of this study is to demonstrate 
the application of these methods to a case study using outcomes of disease man-
agement programs for Cardio-Vascular Risk Management (CVRM: n= 9) and Chronic 
Obstructive Pulmonary Disease (COPD: n= 4), prospectively monitored over a two-
year period. Methods: Performance scores were grouped according to the triple 
aim framework for the three aims of integrated care: 1) improving population health 
outcomes, 2) improving patient experience and 3) reducing costs. Included indi-
cators were the EuroQol-5D, Short-Form-36, smoking and physical activity levels, 
the PACIC (Patient Assessment of Chronic Illness Care) and various cost measure-
ments. Estimation was done by means of the average predicted outcomes from a 
generalised linear model. To increase comparability between programs a multi-
nomial generalisation of propensity score matching (PSM) was applied. Results: 
Differences between the estimated treatment effects were expected based on the 
comprehensiveness of their interventions, e.g. estimated smoking rate was 28% in 
our most comprehensive COPD program, compared to 38% in our least significant 
program. PSM influenced the results, especially for costs and to a lesser extent 
for different dimensions of the EuroQol-5D. Overall, CVRM programs were more 
susceptible to changes resulting from PSM, which may be attributed to the higher 
number of programs. ConClusions: The proposed econometric methods offer a 
novel way to estimate performance scores from outcomes data in disease manage-
ment programs. The estimated performance matrix offers useful distinctiveness 
between criteria and programs as an input for follow-up studies which further 
explore the performance matrix or attach relative weights to each performance 
indicator to allow a formal MCDA.
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telePhone VeRSuS face-to-face inteRViewS foR Patient-RePoRteD 
outcoMe inStRuMent DeVeloPMent
Mazar I, Lamoureux R, Ojo O, Kevane G, Banderas B, Stokes J, Shields A
Adelphi Values USA, Boston, MA, USA
objeCtives: This study provides clinical researchers with guidance for determin-
ing the appropriateness of telephone versus face-to-face (F2F) interview methods 
when conducting patient-centered qualitative research to inform instrument devel-
opment for use in regulated clinical trials. Methods: The benefits and limita-
tions of telephone versus F2F interviews were identified from the peer-reviewed 
literature (N= 15 studies) and discussed in the context of our own experiences 
conducting approximately 90 qualitative patient interview studies in the past five 
years. Results: Evidence suggests a variety of convenience benefits associated 
with telephone interviews (e.g., cost, access to patients) and that, overall, while 
some information is sacrificed (e.g., non-verbal communications), little to no data 
quality is lost when conducting interviews via telephone versus in-person. However, 
experience suggests instances in which data quality between telephone and F2F 
interviews can vary dependent on purpose of interview and target patient popula-
tion. With respect to the purpose of the interview, telephone methods lend them-
selves best for concept elicitation, while in-person methods may be more suitable 
for cognitive debriefing, mode of administration equivalency, and usability testing. 
With regard to target patient population, telephone methods may be appropriate for 
less vulnerable patient populations and/or well-defined disease areas, but less so for 
extremely sick or physically or emotionally compromised patients. ConClusions: 
Researchers developing instruments for use in regulated trials can consider tel-
ephone interviews viable for capturing qualitative patient data; however, the meth-
od’s suitability varies depending on the purpose of the interviews and the target 
patient population. Additionally, some of the perceived “convenience” benefits of 
telephone interviews may not be fully realized when weighed against some surpris-
ing challenges inherent to their conduct including family members’ presence during 
interviews and frequent tardiness. Practical guidance for the selection of interview 
mode is provided and solutions to address practical challenges associated with 
phone interviews are discussed.
ReSeaRch on MethoDS – Statistical Methods
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inteRPReting ReSultS fRoM BayeSian netwoRk Meta-analySeS (nMa): a 
guiDe foR non-StatiSticianS
Pacou M1, Taieb V2, Belhadi D2, Mesana L3, Gauthier A2
1Amaris, Paris, France, 2Amaris, London, UK, 3Amaris London, London, UK
objeCtives: Bayesian NMAs enable us to report results based on probabilities, 
treatment ranking and predictions and are increasingly used to support decision-
making in HTAs. However, there is a lack of guidance on how to report and inter-
pret results from Bayesian analyses. In addition, the complexity of this type of 
analyses makes these findings difficult to understand by analysts not trained in 
Bayesian statistics. We aim to define in simple terms the key concepts behind 
Bayesian methodology and present a guide to help non-statisticians understand 
and interpret findings from Bayesian NMAs. Methods: Majorguidelines (incl. 
Some items influenced by DIF might be another potential problem. Further studies 
on item effects are needed in reporting quality of life.
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Tyupa S1, Wild D2
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objeCtives: The essence of translatability assessment (TA) is to identify potential 
translation problems before the linguistic validation process of PRO and HRQoL 
measures begins; this means that any issues can be resolved prior to the beginning 
of the translation which will improve the quality of the translation, the harmoniza-
tion between language versions and the cultural validity of the measure. It is an 
important step in the development of new measures but there is a lack of guidance 
on the optimal methodology including the number of and experience levels of 
linguists and that need to be involved in the TA itself. The objective of the present 
study was to establish the optimal number of linguists required in a TA process and 
to qualitatively explore any differences based on experience levels. Methods: A 
study was carried out, which involved 18 translators, all native speakers of Polish 
and proficient in English, who individually completed a TA of a schizophrenia-
specific measure (SQLS-R4) where they were presented with the items and response 
options and asked to comment on their translatability into Polish. Results: The 
results show extreme variation in the number and nature of problems identified 
between translators. For example, some translators made 2 comments for the total 
of 40 items presented for assessment, whereas others made over 15 comments. An 
assessment of the number and nature of the comments in relation to the experience 
of the translators suggest that those translators with more experience were able to 
provide more detail around their concerns. This provides strong evidence for the 
claim that differences in TA may be caused not by actual linguistic issues but by 
idiosyncrasies of individual translators. ConClusions: Based on the results, it is 
suggested to involve at least two translators per given language for TA.
PRM201
SoMething olD, SoMething BoRRoweD, SoMething new: a DiRect 
coMPaRiSon of thRee QualitatiVe elicitation MethoDS
Kitchen H1, Willgoss TG1, Meysner S1, Trigg A1, Dickinson S2, Humphrey L1
1Abacus International, Manchester, UK, 2National Ankylosing Spondylitis Society, London, UK
objeCtives: Innovative approaches in patient-reported outcomes (PRO) research 
are widely sought. Yet no published research has prospectively compared traditional 
methods for gathering patient insight with novel methods. In this groundbreaking 
study, aimed at identifying patient-reported symptoms of Ankylosing Spondylitis 
(AS), we explored the value of traditional interview methods against social media 
methods and Group Concept Mapping (GCM). Methods: Three methodologies 
were utilized: 1. Open-ended interviews; 2. online AS patient forums; 3. GCM. 
Participants with AS were recruited from National Ankylosing Spondylitis Society 
(NASS). Interviews and social media data were analysed using ATLAS.ti. GCM was 
conducted on Concept Systems Global MAX software, utilizing multivariate and 
cluster analysis. Analysis for each methodology was performed by an independent 
researcher to ensure impartiality. Three conceptual models of AS symptoms were 
developed based on data from each methodology. Results: Participants completed 
interviews (n= 12) or a GCM exercise (n= 20). Of 14 social media sources identified, 
two met pre-defined criteria; 100 posts were analysed. From a scientific perspective, 
the conceptual models derived from each methodology were broadly compara-
ble supporting the use of novel approaches (in addition to traditional methods) to 
generate patient insights – variations in the conceptual models (and the reasons 
why) will be presented. From a practical perspective, time and cost are substan-
tive when interviewing but are significantly less when using social media data 
or GCM. Furthermore, the ability to perform robust quantitative analysis in GCM 
is particularly advantageous. ConClusions: Methodological advancement is key 
to progress in outcomes research. Without advancing new methods, we cannot 
develop as a field of scientific inquiry. Typically, researchers intimate the relative 
benefits of one method over another. However, in this first study to prospectively 
compare novel with traditional PRO methods, we demonstrated the added value 
of two new approaches and laid bare the scientific and practical considerations for 
qualitative PRO research design.
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anchoRing BiaS in tto ValuationS
Garcia-Molina M, Chicaiza  Becerra LA
Universidad Nacional de Colombia, Bogota, Colombia
objeCtives: Time trade-off (TTO) is one of the main methodologies for eliciting 
health-states utilities in order to determine values. There are large differences in 
implementation methods and results. Anchoring is a cognitive bias that arises 
when answers to a question are attracted by otherwise irrelevant information. 
Anchoring was found in Lead-time TTO as lead times attracted valuations. This 
study enquiries whether the starting point in the TTO iteration procedure induces 
anchoring. Methods: 89 economics students aged 18 to 25 valued five EQ-5D 
health states using TTO. The horizon was 40 years, so that the results were close to 
their life expectancy. The respondents were randomly allocated to two groups. For 
the first group, the first question compared 40 years in perfect health to 40 years 
in the valued health state. For the second group, the first question compared 20 
years in perfect health to 40 years in the valued health state. Then it went up or 
down depending on the answer. Anchoring was expected to appear in the form of 
higher valuations for the group starting from 40 than for the group starting from 20. 
Only states better than death were considered. Worse than death valuations were 
excluded from the health-state sample. Results: The mean valuation for the 40 
groups was higher than for the 20 group for each health state. The difference in 
means was significant at 5% for three health states and at 10% for another one. It 
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objeCtives: Heterogeneity can distort traditional indirect comparisons of treat-
ments. Simulated treatment comparisons (STC) can overcome this with regres-
sion equations to balance differences in populations. Equations are derived using 
patient-level data from one trial (drug A, index); however, only mean values of 
predictors are typically known for the comparator (B). Thus, adjusted results must 
be generated by plugging these means in the equation, which can be biased for 
non-linear outcomes (e.g., time-to-event) since it yields the geometric rather than 
the required arithmetic mean. We describe a solution and illustrate its application 
in an STC of treatments of non-valvular atrial fibrillation (NVAF). Methods: Data 
from the trial of drug A were used to derive an equation for the rate of major bleeds 
(MB) using Poisson regression. Predictors included gender, age, region, history of 
stroke/transient ischemic attack, hypertension, diabetes, renal dysfunction, prior 
use of various treatments. To avoid non-linearity bias, patient profiles were simu-
lated by sampling predictor values from a multivariate-normal distribution with 
means set to drug B’s population and covariance matrix derived from the index 
trial. The average predicted rate for simulated patients represents the adjusted 
MB rate. To demonstrate that the approach works, we also apply it to the index 
trial. Results: A rate of 21 MBs/1000 person-years were observed with drug A. The 
predicted rate at the means of predictors of patients on drug A produced an estimate 
of 19 (16.4-21.0), whereas the mean of predicted rates with actual profiles was 22 
(15.1-31.9). Repeating the calculations with simulated patients yielded 22.5 (15.3-
33.0). The simulated MB rate in patients matching of the population of drug B was 
30 (20.5-45.1), which contrasted with its observed rate (36.0) yielded a rate ratio of 
0.84 (0.56-1.27). ConClusions: Predicting outcomes with a simulated comparator 
population produces accurate adjusted results for use in STCs.
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the uSe of inDiRect coMPaRiSonS in MeDicineS eValuation foR theiR 
acceSS to ReiMBuRSeMent By the haS
Guichard M1, D’Andon A1, Rumeau Pichon C2, Borget I3
1Haute Autorité de Santé, Saint Denis La Plaine, France, 2Haute Autorité de santé, Saint-Denis La 
Plaine, France, 3Institut Gustave Roussy, Villejuif, France
objeCtives: To evaluate new medicines, Health Technology Assessment (HTA) 
agencies must have comparative data. With the lack of randomized trials versus all 
comparators, pharmaceutical companies have increasingly used indirect compari-
sons. The objective of the present study was to describe the impact of the method-
ology of the indirect comparison both on the ASMR determination and efficiency 
opinions given by the French National Authority for Health (HAS). Methods: Two 
retrospective studies were conducted in order to select HTA opinions mention-
ing indirect comparisons (using the keywords “indirect” or “network”) using inter-
nal databases of HAS. The first study was related on HTA opinions given by the 
Transparency Committee (TC) from July 2009 to October 2014. The second study 
analyzed efficiency opinions issued by the Commission of Economic Evaluation 
and Public Health (CEESP) from October 2013 to December 2014. For each study, 
we recorded: the method of indirect comparison used, the acceptability, the criti-
cisms and the impact on decision-making. Results: We identified 61 indirect com-
parisons from HTA opinions given by the TC. Among these, the TC considered 30 
methodologically unacceptable. Network meta-analysis, the method recommended 
by the HAS, was used in 46% of cases. Only 6/61 indirect comparisons were valid, 
allowing to prioritize the treatment, and were consistent with the « improvement 
of the medical service provided » (ASMR) assigned. In the second study out of 14 
opinions of efficiency given by the CEESP, 4 included indirect comparisons (29%) and 
they were all considered as acceptable. ConClusions: For the TC, the results of 
indirect comparisons are considered as complementary evidence, and are not deci-
sive elements for the ASMR opinion. Conversely, CEESP accepted more frequently 
results of indirect comparisons into economic evaluations. This apparent difference 
in considering and using indirect comparisons by these two commissions of the 
HAS may be explained by their different objectives.
PRM210
a MethoD BaSeD on the ReMaining Value of PeRfect infoRMation foR 
the SaMPle Size calculation in RanDoMizeD tRial-BaSeD  
coSt-effectiVeneSS analySeS
Bader C, Donadel M, Maillard A, Benard A
University Hospital Bordeaux, Bordeaux, France
objeCtives: To propose a sample size calculation method for randomized trial-
based cost-effectiveness analyses (RTBCEA), coherent with recommendations to 
express uncertainty through cost-effectiveness probabilities and expected value of 
information. Methods: Let’s estimate the sample size of a RTBCEA with 2 parallel-
groups of equal size n, assuming equal variance of costs (s²C) and effectiveness 
(s²E) in each group. Our method is based on the incremental net monetary benefit 
(b~N(μ b,σ ²b)). A realization of this random variable in the planned RTBCEA would 
yield a sampling distribution of mean μ b and variance 2σ ²bi/n, where σ ²biis the vari-
ance of the individual net monetary benefit in each group. σ ²bi= λ ²σ ²E+σ ²C–2λ ρ σ Eσ C, 
where λ is the ceiling cost-effectiveness ratio, and ρ the correlation between cost and 
effectiveness. Using this sampling distribution of b, the remaining value of perfect 
information (or the expected value of perfect information depending on n (EVPI(n))) 
is calculated, specifying the size of the target population (N) and a discount rate 
(r). The total cost of the planned RTBCEA is defined by a fixed cost (Cf) and a cost/
patient (Cv). The optimal sample size of one arm in the planned RTBCEA is n when 
EVPI(n)= Cf+2nCv. An application compares sample sizes calculated through our 
method and through a method using statistical inference. Results: Application’s 
data are: σ C= 2100€ , σ E= 2100QALY, ρ = 0.1, λ = 20000€ /QALY, N= 52000/year, r= 0.04, 
time horizon for the calculation of EVPI= 20 years, difference in mean costs= -168€ , 
and difference in mean QALY= 0.04. σ ²bi= 9162002.53 Cf= 81531€ , and Cv= 2257.25€ 
The optimal sample size estimated through our method was 123 patients/group, 
compared to 153/group using the method based on a statistical test with a 80% 
power and a 5% alpha risk. ConClusions: Our method is perfectly coherent with 
recommendations for analyzing cost-effectiveness data and sets the optimal sample 
NICE, IQWiG, CADTH, HAS and EUnetHTA) were reviewed to identify recommen-
dations made forBayesian NMAs in the context of HTAs. Examples of HTA sub-
missions from manufacturers were used to identify how Bayesian results are 
reported in practiceIn order to ensure clarity and simplicity, a guide to interpret 
these results was developed in collaboration with analysts not trained in Bayesian 
statistics. This guide is illustrated with an example of NMA. Results: Bayesian 
analyses are often used in the conduct of NMAs meant to inform cost-effectiveness 
models. Results are generally reported as median or mean of the posterior distribu-
tion, standard deviation, 95% credible intervals and forest plots. Additional results 
include the probability for each treatment of ranking first, the SUCRA (Surface 
Under the Cumulative Ranking) and the probability for the intervention to perform 
better than its comparators. Although it could help interpret the findings, graphi-
cal representation of the posterior distribution is not commonly reported in HTA. 
Sensitivity analyses are also often reported, mainly to assess the robustness of 
the results. ConClusions: Our guide is useful to analysts not trained in Bayesian 
statistics for decision-making purposes in the context of HTA submissions. More 
specifically, it is a straightforward reference tool for using NMA results to populate 
cost-effectiveness models.
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non-aDheRence anD non-PeRSiStence ShoulD Be analyzeD SePaRately: 
the exaMPle of MethotRexate (Mtx) theRaPy in the theRaPy of newly 
tReateD RheuMatoiD aRthRitiS in geRMany
Mueller S1, Krueger K2, Flacke J3, Heinrich H3, Fuchs A4, Maywald U5, Wilke T6
1IPAM, Wismar, Germany, 2Praxiszentrum St. Bonifatius, München, Germany, 3Roche Pharma 
AG, Grenzach, Germany, 4AOK PLUS, Dresden, Germany, 5AOK Plus, Dresden, Germany, 6Ingress 
Health, Wismar, Germany
objeCtives: In most adherence studies, results are shown as overall medication 
possession ratio (MPR). The aim of this study was to show how non-adherence 
(NA) rates of German patients with rheumatoide arthritis (RA) having initiated a 
methotrexate (MTX) therapy change if adherence is analyzed as overall MPR includ-
ing periods of therapy discontinuation (NP) or, alternatively, for periods of treat-
ment continuation only. Methods: Claims data from a German sickness fund 
(AOK PLUS) covering the years 2010-2013 were used. Minimum observational period 
from first MTX-prescription onwards was defined to be 24 months. A medication gap 
of more than 12 weeks was considered to be NP. Adherence was calculated during 
a 12 or 24 month follow-up in two scenarios (for whole period versus for periods 
of therapy continuation between first and last prescription only). NA was defined 
as MPR< 80%. Results: 1,157 MTX-naïve patients (no MTX-prescription in 2010) 
were identified (mean age 61.6 years, 71.8% female, average Charlson Comorbidity 
Index without age factor 2.0). Overall MPR from first prescription until end of the 
12- or 24-months-obserational period for all these patients was 69.7 or 59.9%. Based 
on this, percentage of NA patients was 41.2 or 53.3%. However, 21.2% of patients 
discontinued MTX therapy (NP) within the first 24 months; mean time to discon-
tinuation was 29.1 weeks. If adherence was assessed for periods of therapy con-
tinuation only, the resulting MPR was 95.0% with only 6.4% of patients affected by 
NA. ConClusions: NA and NP describe different real-world phenomena in the 
drug-based treatment of patients and may also be explained by different causes. So, 
NP and NA should be assessed separately. Our analysis shows that the percentage 
of patients poorly implementing therapy is over-estimated if NA is not calculated 
for periods of therapy continuation only.
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uSing tangent line SegMentS to DeteRMine StatiStical DiffeRenceS 
Between SuRViVal cuRVeS at a Single Point in tiMe
Wasser T1, Kern DM2, Eisenberg D1
1HealthCore Inc., Wilmington, DE, USA, 2HealthCore Inc, Wilmington, DE, USA
objeCtives: Typical survival analysis examines differences in curves across the 
entire spectrum of time. Often the research question relates to differences in sur-
vival at a single point in time without considering other aspects of the survival 
curve. Methods: This research used data from the United States Surveillance, 
Epidemiology and End Results Program (US-SEER), comparing cervical and ovar-
ian cancer 5-year survival rates from 2007-2011. The steps in this analysis are: 1. 
Calculate Kaplan-Meier curve (or any survival curve) using standard methods, 2. 
Calculate the quadratic curve for the survival measure and record the formula. 
3. Using the point of interest (in this example 12 months) calculate the tangent 
line for that point, using the derivative power method. These two slope values are 
tested against each other using standard slope comparisons. 4. Use the standard 
error of the model for the quadratic equation for significance testing. 5. Test the 
difference between slopes for significance using standard statistical methods for 
slope comparisons. Results: Quadratic formulas were determined for both ovarian 
and cervical cancer survival curves and the tangent lines were calculated using the 
derivative for the equation from the curve. This resulted in two slope values at 12 
months (cervical 4.116 and ovarian 7.151). Using the standard errors for the cervix 
and ovarian groups (2.268 and 3.854 respectively), the Z-value= 0.6787 and p= 0.497, 
indicating the trajectory of survival for cervical and ovarian cancer are not statisti-
cally different from each other even though the point estimates of survival (88.4% 
for cervical; 75.4% for ovarian) are statistically different from each other at that 
point. ConClusions: The strengths of this method is that a single point difference 
test can be conducted for a single point in time based on the trajectory of the line. 
This method does not pool the data across all points. Several other examples will 
be presented graphically.
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